NanoString Technologies Releases First Quarter 2014 Financial Results
GlobeNewswire - Wed May 07, 3:46PM CDT
- Strong Q1 2014 Revenue Growth of 54% Year over Year -
NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay
Business Wire - Tue May 06, 3:50PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna(R) Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.
NanoString Technologies to Participate in the 2014 Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Thu May 01, 3:11PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Bank of America Merrill Lynch Healthcare Conference in Las Vegas.
NanoString Technologies Appoints Veteran Diagnostics Executive Tina S. Nova, Ph.D. to Its Board of Directors
GlobeNewswire - Wed Apr 30, 3:12PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of veteran diagnostics executive Tina S. Nova, Ph.D. to its Board of Directors. Dr. Nova will also join the Board's Compensation Committee.
NanoString Technologies to Release First Quarter 2014 Financial Results and Host Conference Call on Wednesday, May 7, 2014
GlobeNewswire - Wed Apr 16, 3:16PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2014 first quarter financial results after the close of trading on Wednesday, May 7, 2014. Company management will host an investment community conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NanoString Technologies Introduces Novel PanCancer Gene Expression Panel for Multiplexed Pathway Analysis
Business Wire - Mon Apr 07, 6:30AM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the nCounter(R) PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a unique way for translational researchers to investigate cancer biology across all major cancer pathways. The company made the announcement at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
NanoString Technologies enters into USD45m six year term loan agreement with Capital Royalty
M2 - Fri Apr 04, 5:31AM CDT
Life science company NanoString Technologies (NasdaqGM:NSTG) disclosed on Thursday the launch of up to USD45m term loan agreement with Capital Royalty and certain of its affiliates.
NanoString Technologies Announces $45 Million Term Loan Agreement With Capital Royalty
GlobeNewswire - Thu Apr 03, 3:03PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a term loan agreement with Capital Royalty L.P. and certain of its affiliates. The agreement provides NanoString with up to $45 million of available borrowing capacity.
Single Cell Omics Trends - Global Market Overivew 2014
M2 - Tue Apr 01, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5vvw9/single_cell_omics) has announced the addition of the "Single Cell Omics Trends" report to their offering. Single Cell Omics, a cutting edge technology, mainly integrates advanced technology with biology for a variety of single cell applications. The technology helps to study single cells at a much deeper level which allows identifying important genomic variations. The report analyzes and presents an overview of Single Cell Omics market worldwide. The report also offers global market estimates and projections for Single Cell Omics technology and products in US dollars for years 2012 through 2017. Key geographic market quantitatively analysed include the Unites States, Europe, Asia Pacific, and Japan. Supported with 6 market data tables, the report provides a review of market trends, application areas, growth opportunities, and challenges. The data table highlights global Single Cell Omics market by applications, technology, product, region, and field of study. Key Topics Covered: 1. SINGLE CELL OMICS - A MARKET OVERVIEW - Single Cell Analysis - A Revolutionary Technology Changing Market Dynamics - Single Cell Genomics - An Introduction - Biological Research Shifting from Tissue/Organ Level Approach to a Single Cell - Single Cell Analysis - Role of Omics - Single-Cell Isolation Techniques - Single Cell Omics - Applications - Single Cell Omics - Major Application Areas - SCA Devices - Technological Improvements - Single Cell Omics - Growth Opportunities Vs. Challenges - Global Single Cell Omics Market to Register Mammoth Growth Rate - Single Cell Omics Market by Technology - Single Cell Omics Market by Field of Study - Single Cell Omics Market by Applications - Picodroplet Single Cell Analysis Technology Witnesses Significant Surge - Major Players in the Single Cell Isolation Market - Major Players in the Single Cell Sample Preparation Market - Major Players in the Single Cell Genomic Analysis Market 2. RECENT INDUSTRY ACTIVITY - Genome Institute of Singapore and Fluidigm Open GIS-Fluidigm - Single-Cell Omics Center in Singapore - Sphere Fluidics Develops New Technologies for Single Cell Analysis 3. MARKET PARTICIPANTS - BD Biosciences - BioNano Genomics, Inc. - DVS Sciences, Inc. - Fluidigm Corporation - Fluxion Biosciences, Inc. - Life Technologies Corporation - Molecular Machines & Industries (MMI) - NanoString Technologies, Inc. - NuGEN Technologies, Inc. - Qiagen NV - Roche Applied Science - Silicon Biosystems - Sphere Fluidics Ltd. - Tataa Biocenter AB - Thermo Fisher, HCA Company 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/j5...cell_omics
Newly Published Analytical Validation Study Shows Precision and Reproducibility of PAM50-Based Prosigna Breast Cancer Assay in Multiple Clinical Testing Laboratories
Business Wire - Thu Mar 13, 3:30PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in the journal BMC Cancer demonstrates the analytical validity of the PAM50-based Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay. Based on highly concordant results across multiple clinical laboratory sites, technicians, and manufacturing lots of Prosigna reagents, the authors concluded that the study provides a strong body of evidence supporting the decentralized use of the Prosigna Assay on the nCounter Dx Analysis System as a prognostic tool for the risk of recurrence (ROR) in selected breast cancer patients.
NanoString Technologies Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Feb 26, 3:09PM CST
- Strong Q4 2013 Revenue Growth of 56% Year over Year -
NanoString Technologies to Participate in the Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Cowen 34 Annual Health Care Conference in Boston.
Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer
Business Wire - Wed Feb 12, 6:30AM CST
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on which the company's Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay is based, accurately assessed the risk of late distant recurrence in postmenopausal women with estrogen receptor-positive (ER+) early-stage breast cancer. The study, titled, "The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer" was conducted by researchers from the Austrian Breast & Colorectal Cancer Study Group and can be found online at: http://clincancerres.aacrjournals.org/content...5.abstract.
NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests From Translational Research Discoveries
Business Wire - Tue Feb 11, 6:30AM CST
NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the global commercial launch of the nCounter Elements(TM) General Purpose Reagents (GPRs), a solution that enables clinical laboratories to independently develop multiplexed genomic assays and then rapidly translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs). The announcement, made at the 21st International Molecular Medicine Tri-Conference (TRI-CON) taking place in San Francisco, February 9 - 14, marks the conclusion of a successful early access program that involved 22 participants from five countries in North America, Europe, and Asia.
NanoString Technologies to Release Fourth Quarter 2013 Financial Results and Host Conference Call on Wednesday, February 26, 2014
GlobeNewswire - Wed Feb 05, 3:05PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 fourth quarter financial results after the close of trading on Wednesday, February 26, 2014. Company management will host an investment community conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NanoString Technologies to Participate in the Leerink Swann Global Healthcare Conference 2014
GlobeNewswire - Wed Jan 29, 3:02PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Leerink Swann Global Healthcare Conference 2014 in New York.
NanoString Technologies Inc prices USD55m in follow-on offering
M2 - Fri Jan 24, 4:18AM CST
Molecular diagnostic company NanoString Technologies Inc reported on Thursday that it has priced a follow-on public offering of USD55m of its common stock.
NanoString Technologies Prices Follow-On Offering
GlobeNewswire - Thu Jan 23, 5:30PM CST
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.
NanoString Technologies Inc announces USD55m in follow-on public offering
M2 - Wed Jan 22, 3:57AM CST
Molecular diagnostic company NanoString Technologies Inc (NasdaqGM:NSTG) reported on Tuesday USD55m proposed follow-on public offering of its common stock.